Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.Daniel Yick Chin Heng, Toni K. Choueiri, Lori Wood et al.|Journal of Clinical Oncology|2015Cited by 6
Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC).Guillermo de Velasco, Toni K. Choueiri, Wanling Xie et al.|Journal of Clinical Oncology|2016Cited by 3
Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).Daniel Yick Chin Heng, Toni K. Choueiri, Igor Stukalin et al.|Journal of Clinical Oncology|2015Cited by 3
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).José Manuel Ruiz Morales, Daniel Yick Chin Heng, J. Connor Wells et al.|Journal of Clinical Oncology|2016Cited by 1
Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC).Haoran Li, Daniel Yick Chin Heng, Toni K. Choueiri et al.|Journal of Clinical Oncology|2015Cited by 0